Interstitial Lung Disease Treatment Guidelines

Interstitial Lung Disease Treatment Guidelines Aim to Relieve Patients’ Symptoms and Enhance Quality of Life

Various guidelines have been created for the treatment of interstitial lung disease, a group of conditions that cause the progressive scarring of lung tissue. As of this time, interstitial lung disease is incurable and the damage it causes cannot be reversed. Therefore, treatment generally is aimed at alleviating associated symptoms using a variety of methods, including the following:

  • Anti-fibrotic medications
  • Anti-inflammatory medications
  • Antibiotics
  • Immunosuppressive medications
  • Nutrition counseling
  • Pulmonary rehabilitation
  • Supplemental oxygen therapy

One of the objectives of interstitial lung disease management is to create a personalized course of treatment specific to a patient’s unique needs. At the Lung Institute, we work toward achieving this goal by offering two different types of stem cell therapy: bone marrow therapy and venous therapy. Both types are geared toward slowing disease progression and improving quality of life.

Both of our stem cell therapy methods are performed in a clinical setting on an outpatient basis over the course of two days. Each method features specific benefits that allow us to choose the approach that will best suit a patient’s individual circumstances. For example, while bone marrow has been shown to contain more adult stem cells than peripheral blood, the process used to extract stem cells from a patient’s blood tends to be less invasive than that used for bone marrow therapy. Above all, our goal is to help our patients find a specialized plan of treatment that will allow them to breathe easier.

If you are living with interstitial lung disease, please contact the Lung Institute today at (800) 729-3065. We would be happy to provide you with additional information on interstitial lung disease treatment guidelines and help you determine whether stem cell therapy may be a beneficial addition to your course of treatment.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.